Founded in neuropathological expertise.
Our sophisticated diffusion analysis is based on neuropathology, and the correlations between microscopic data and MRI analysis. Based at the University of Oxford, Dr Steven Chance and Professor Mark Jenkinson combined their world class expertise to develop CDM® technology.
Today, this breakthrough technology can provide an assessment of brain health based on changes at the cellular level, for dementia patients, which previously could only be analysed at post-mortem.
Dr Steven Chance (CEO & Co-Founder) was Associate Professor in Clinical Neurosciences at the University of Oxford. He has 20 years combined pathology and neuroscience experience researching the microscopic basis of brain disease. He is a world authority on the cortical disarray in dementia that is measured by the CDM® technology. He taught Medicine at Corpus Christi College and Human Sciences at Wadham College.
Professor Mark Jenkinson (Co-Founder) is at the University of Oxford and is one of the architects of the world’s leading MRI analysis software suite (FSL). He is one of the highest cited MRI authors globally and is editor of a new series of books on MR imaging.